摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 4-(aminomethyl)-2-hydroxybenzoate hydrochloride

中文名称
——
中文别名
——
英文名称
methyl 4-(aminomethyl)-2-hydroxybenzoate hydrochloride
英文别名
methyl 4-aminomethylsalicylate hydrochloride;4-aminomethyl-salicylic acid methyl ester hydrochloride;methyl 4-(aminomethyl)-2-hydroxybenzoate;hydrochloride
methyl 4-(aminomethyl)-2-hydroxybenzoate hydrochloride化学式
CAS
——
化学式
C9H11NO3*ClH
mdl
——
分子量
217.652
InChiKey
BRPJAORAEANAQU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.06
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    72.6
  • 氢给体数:
    3
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    酪氨酸激酶抑制剂。2. 2,2'-二硫代双(1H-吲哚-3-烷基酰胺)的合成及其对表皮生长因子受体和pp60v-src蛋白酪氨酸激酶的抑制活性研究。
    摘要:
    通过1H-吲哚-3-烷酰胺(8)与S2Cl2的反应,并分离,制备了一系列2,2'-二硫代双(1H-吲哚-3-烷酸)类酪氨酸激酶抑制剂的酰胺类似物。从形成的一硫化物,二硫化物和三硫化物的初始混合物中分离出所需的二硫化物。这些酰胺在体外针对表皮生长因子受体和pp60v-src蛋白酪氨酸激酶进行了评估。对EGF受体酪氨酸激酶的抑制活性是链长依赖性的,丙酰胺是最有效的。似乎不需要酰胺功能中的氢键供体功能,其中最有力的是N-苄基酰胺(IC50 = 0.85 microM)。苄基环上的进一步取代没有增加效力,并且丙酰胺侧链的α-位置的取代是可接受的。水溶性α-NH2衍生物对酶显示出良好的抑制活性,是成纤维细胞中细胞生长的有效抑制剂,并选择性抑制细胞内酪氨酸磷酸化模式。通常,非受体激酶pp60v-src比EGF受体激酶对这些化合物的抑制更为敏感,但结构活性关系不那么明显。
    DOI:
    10.1021/jm00031a009
  • 作为产物:
    描述:
    methyl 4-(azidomethyl)-2-hydroxybenzoate 、 4-溴甲基水杨酸甲酯 盐酸氢气 作用下, 以 甲醇氢氧化钾乙醇 为溶剂, 以65%的产率得到methyl 4-(aminomethyl)-2-hydroxybenzoate hydrochloride
    参考文献:
    名称:
    Boronic compound complexing reagents and highly stable complexes
    摘要:
    公开了硼化合物络合试剂、这些试剂的中间试剂以及合成这些试剂的方法。这些试剂,包括通用化学式I和通用化学式II所示的试剂,可以在此处描述的进一步反应后,与硼酸化合物(如苯硼酸或其衍生物)形成络合物。
    公开号:
    US05777148A1
点击查看最新优质反应信息

文献信息

  • 2-thioindoles (selenoindoles) and related disulfides (selenides) which
    申请人:Warner-Lambert
    公开号:US05464861A1
    公开(公告)日:1995-11-07
    2-Thioindoles (2-selenoindoles) and analogous 2-indolinethione (2-indolineselenone) and polysulfide (selenide) compounds, salts thereof, methods of production, intermediates in their production, pharmaceutical compositions containing said compounds, and methods for inhibiting protein kinase dependent disease in a mammal or treating aberrant cell growth in a mammal, using said compositions, are disclosed.
    本文揭示了2-吲哚(2-吲哚)及类似的2-吲哚酮(2-吲哚酮)和聚硫化物化物)化合物,以及其盐、生产方法、生产中间体、含有该类化合物的药物组合物,以及使用这些组合物来抑制蛋白激酶依赖性疾病或治疗哺乳动物中的异常细胞生长的方法。
  • Boronic compound complexing reagents and complexes
    申请人:Prolinx, Inc.
    公开号:US05847192A1
    公开(公告)日:1998-12-08
    Boron compound complexing reagents and methods of synthesizing these reagents are disclosed. These reagents, including those shown as General Formula I and General Formula II may be used, after further reactions described herein, to complex with boronic compounds, such as phenylboronic acid or derivatives thereof. ##STR1##
    公开了化合物络合试剂及合成这些试剂的方法。这些试剂,包括通用化学式I和通用化学式II所示的试剂,经过本文所述的进一步反应后,可用于与化合物(如苯硼酸或其衍生物)形成络合物。
  • Methods for the preparation of chemically misaminoacylated tRNA via protective groups
    申请人:AMBERGEN, INC.
    公开号:US20030219780A1
    公开(公告)日:2003-11-27
    The present invention relates to methods for the preparation of chemically aminoacylated tRNAs for the purpose of introduction of markers into nascent proteins. The present invention also relates to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system utilizing chemically aminoacylated tRNAs. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system.
    本发明涉及用于制备化学酰化tRNA的方法,目的是将标记物引入新生蛋白质中。本发明还涉及用于在细胞或无细胞翻译系统中翻译的新生蛋白质的非放射性标记、检测、定量和分离的方法,利用化学酰化的tRNA。tRNA分子被非放射性标记物误酰化,这些标记物可以是非天然氨基酸氨基酸类似物或衍生物。标记物可能包括可切割的基团、可检测的标签、报告性质,其中蛋白质中包含的标记物可以与未包含的标记物区分开来,或者促进检测和从翻译系统的其他组分中分离新生蛋白质的耦合剂。
  • Bifunctional boronic compound complexing reagents and complexes
    申请人:Prolinx, Inc.
    公开号:US06156884A1
    公开(公告)日:2000-12-05
    Reagents suitable for the modification of a bioactive species for the purpose of incorporating a bifunctional boronic compound complexing moiety for subsequent conjugation to a different (or the same) bioactive species having pendant phenylboronic acid moieties of General Formula 1, ##STR1## wherein group R is an electrophilic or nucleophilic moiety suitable for reaction of the putative bifunctional boronic compound complexing reagent with a bioactive species, wherein group R.sub.2 is selected from one of H and OH moieties, and wherein group R.sub.3 is selected from one of an alkyl and a methylene bearing an electronegative substituent. Group Z is a spacer selected from (CH.sub.2).sub.n and CH.sub.2 O(CH.sub.2 CH.sub.2 O).sub.n.sbsb.2, wherein n is an integer of from 1 to 5, and wherein n.sub.2 is an integer of from 1 to 4. Each of group Z.sub.2 and Z.sub.3 is a spacer selected from CH.sub.2 Ar, CH.sub.2 CONHCH.sub.2 Ar, CH.sub.2 CONH(CH.sub.2).sub.n.sbsb.3 CO--NHCH.sub.2 Ar, and (CH.sub.2).sub.n.sbsb.4 NHCO(CH.sub.2).sub.n.sbsb.5 CONHCH.sub.2 Ar, wherein the group Ar represents the aromatic ring in the reagent of General Formula I to which the spacer Z.sub.2 or Z.sub.3 is appended, wherein n.sub.3 is an integer of from 1 to 5, wherein n.sub.4 is an integer selected from one of 2 and 3, and wherein n.sub.5 is an integer of from 1 to 4. Reaction of a reagent of General Formula I with a bioactive species affords a conjugate having pendant putative bifunctional boronic compound complexing moieties. (one or more) The conjugate may be further reacted with hydroxylamine (NH.sub.2 OH) by amidation of the benzoic acid ester moiety to afford a class of bifunctional boronic compound complexing conjugate, e.g., conjugate with one or more pendant bifunctional boronic compound complexing moieties.
    适用于修改生物活性物种的试剂,目的是将具有双功能硼酸化合物络合基团的试剂并入(或相同的)具有苯硼酸酯基团的生物活性物种,其通式为1,其中基团R是适合用于反应假定的双功能硼酸化合物络合试剂与生物活性物种的亲电性或亲核性基团,其中基团R.sub.2从H和OH基团中选择,基团R.sub.3从带有电负取代基团的烷基和亚甲基中选择。基团Z是选择自(CH.sub.2).sub.n和CH.sub.2 O(CH.sub.2 CH.sub.2 O).sub.n.sbsb.2的间隔基团,其中n为1至5的整数,n.sub.2为1至4的整数。群Z.sub.2和Z.sub.3中的每个都是选择自CH.sub.2 Ar、CH.sub.2 CONHCH.sub.2 Ar、CH.sub.2 CONH(CH.sub.2).sub.n.sbsb.3 CO--NHCH.sub.2 Ar和(CH.sub.2).sub.n.sbsb.4 NHCO(CH.sub.2).sub.n.sbsb.5 CONHCH.sub.2 Ar的间隔基团,其中群Ar代表通式I中试剂中连接的间隔基团Z.sub.2或Z.sub.3的芳香环,其中n.sub.3为1至5的整数,n.sub.4为2或3中的一个整数,n.sub.5为1至4的整数。通式I的试剂与生物活性物种的反应产生具有悬挂假定双功能硼酸化合物络合基团的结合物(一个或多个)。结合物可以进一步与羟胺(NH.sub.2 OH)反应,通过苯甲酸酯基团的酰胺化作用形成一类双功能硼酸化合物络合结合物,例如,具有一个或多个悬挂双功能硼酸化合物络合基团的结合物。
  • Sensor surfaces for detecting analytes
    申请人:Prolinx Incorporated
    公开号:US20020192722A1
    公开(公告)日:2002-12-19
    The present invention provides a sensor surface comprising: a substrate coated with a free electron metal; and a matrix layer disposed on the free electron metal, wherein the matrix layer comprises an organic compound having a boronic acid complexing moiety. The matrix is preferably a self-assembled monolayer (SAM), a mixed self-assembled monolayer (mSAM), or combinations thereof.
    本发明提供了一种传感器表面,包括:涂有自由电子属的基板;以及位于自由电子属上的基质层,其中基质层包括具有硼酸络合基团的有机化合物。该基质最好是自组装单分子层(SAM)、混合自组装单分子层(mSAM)或它们的组合。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫